← All indications
Endocrine Gland Neoplasms
Tumors or cancer of the ENDOCRINE GLANDS.
Subtype terms (9)
More specific conditions that are subtypes of Endocrine Gland Neoplasms in the MeSH hierarchy.
- Adrenal Gland Neoplasms
54 drugs (36 approved, 18 experimental)
- Multiple Endocrine Neoplasia
6 drugs (5 approved, 1 experimental)
- Ovarian Neoplasms
1163 drugs (312 approved, 851 experimental)
- Pancreatic Neoplasms
1361 drugs (372 approved, 989 experimental)
- Paraneoplastic Endocrine Syndromes
- Parathyroid Neoplasms
17 drugs (13 approved, 4 experimental)
- Pituitary Neoplasms
45 drugs (36 approved, 9 experimental)
- Testicular Neoplasms
152 drugs (97 approved, 55 experimental)
- Thyroid Neoplasms
270 drugs (155 approved, 115 experimental)
Drugs by status
Phase 3 trials (3)
Phase 2 trials (11)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (25)
- Roche
- Genentech
- Catalysis SL
- Jubilant Innovation Ltd.
- PharmaMar
- National Cancer Institute (NCI)
- Federation Francophone de Cancerologie Digestive
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Johns Hopkins University
- Nanjing Medical University
- Ohio State University
- Stanford University
- University of Milan
- University of South Florida
- University of Naples Frederico II
- University of Udine
- University of Utah
- Institut Gustave Roussy
- University of Texas at Houston
- University of Genoa
- University of Paris
- University of Perugia
- Johnson and Johnson
- Jiangsu Cancer Institute & Hospital
- Vall d'Hebron Institute of Research, Galatea Clinic
Organization Involved with Phase 1 Indications (4)